Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 08/01/2009 The photo depicts the principle of biochip technology.

    ILM – Screening methods

    Optical screening methods are of huge importance for a broad range of analytical issues. Fluorescence-based methods are highly significant for their high sensitivity amongst other things. Important technological developments have focused for example on reducing sample volumes increasing sample throughput high-throughput screening HTC or on information content high-content screening HCS. With regard to screening methods the ILM is currently…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-screening-methods
  • Article - 07/12/2008

    New kilo laboratory for R&D

    Boehringer Ingelheim has recently officially opened a new kilo laboratory in Biberach. The laboratory produces pharmaceutically active substances for use in pharmaceutical development toxicity testing and the early clinical development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-kilo-laboratory-for-r-d
  • Press release - 07/10/2008

    GENEDATA SCREENER® – specialised data analysis for the identification of high-potential lead structures

    Genedata AG has developed a modular software system known as Genedata Screener that is tailored to screening and hit-to-lead applications. Dr. Timo Wittenberg who works at the companys site in Constance Germany told us about the advantages of the software for identifying high-potential leads.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/genedata-screener-specialised-data-analysis-for-the-identification-of-high-potential-lead-structures
  • Dossier - 29/09/2008 This computer-based picture shows a small blue and red coloured molecule that fits into a gap of a large grey molecule. Such molecular interactions are essential for pharmacological research.

    Drug screening - higher throughput, quicker and more effective thanks to automation

    Over the last few years automation has revolutionised the search for pharmaceutical compounds. Using methods such as high-throughput screening or high-content screening it is possible to analyse thousands of molecule activities very quickly.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-screening-higher-throughput-quicker-and-more-effective-thanks-to-automation
  • Article - 02/09/2008

    Screening with high quality and high throughput

    The Early Discovery department of the research-based pharmaceutical company Nycomed GmbH deals with early drug research from the identification of targets to the generation of lead structures. This process involves high-throughput drug screening. On behalf of www.bio-pro.de Michael Statnik talked with Dr. Stefanie Polej about the process of the automated analysis of molecule activities in the Constance-based company.

    https://www.gesundheitsindustrie-bw.de/en/article/news/screening-with-high-quality-and-high-throughput
  • Article - 22/06/2008

    Nycomed sells oncology programs to 4SC

    Eight projects in the preclinical and first clinical stage will be transferred to 4SC. Nycomed decided not to further invest in oncology RD activities. 4SC develops drug candidates for inflammatory diseases cancer and infectious diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-sells-oncology-programs-to-4sc

Page 2 / 2

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search